Scale -

  • Revenue is 198 Rs Cr; Annual Growth is 22 %; 5 Year CAGR is 14 %; in Bottom Quartile
  • PBT is 2.57 Rs Cr; Annual Growth is 21 %
  • PAT is 9.8 Rs Cr; Annual Growth is 49 %
  • Quarterly Revenue is 47.9 Rs Cr; in Bottom Quartile

Profitability -

  • PAT Margin is 4.95 %; Annual Growth is 23 %; 5 Year CAGR is -21 %
  • PBDIT Margin is 11.47 %; Continuous Decline over 3 years; 5 Year CAGR is -15 %
  • Quarterly Profit margin is 4 %; in Bottom Quartile

Return -

  • ROCE is 5.45 %; Continuous Decline over 3 years; 5 Year CAGR is -19 %
  • ROA is 2.59 %; 5 Year CAGR is -21 %
  • ROE is 3.61 %; 5 Year CAGR is -23 %

Efficiency -

  • Quick Ratio is 1.75; Annual Growth is 34 %; Continuous Growth over 3 years
  • Current Ratio is 2.54; Continuous Growth over 3 years
  • Inventory Turnover Ratio is 2.99; Continuous Growth over 3 years; in Bottom Quartile
  • Operating cash flow is -33.17 Rs Cr; Annual Decline is -306 %; Continuous Decline over 3 years; in Bottom Quartile

Solvancy -

  • Long term Debt is 6.15 Rs Cr; Annual Growth is 65 %; Continuous Growth over 3 years
  • Total Debt is 47.78 Rs Cr; Annual Growth is 44 %; Continuous Growth over 3 years
  • Debt/Equity is 0.18; Continuous Growth over 3 years

Quality -

  • Current Tax/PAT is 26 %; Annual Decline is -53 %
  • Operating cashflow/ebitda is -146 %; Annual Decline is -260 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/PAT is -338 %; Annual Decline is -172 %; Continuous Decline over 3 years; in Bottom Quartile
  • Change in Inventories/Total Expenses is 4 %; Annual Growth is 154 %; Continuous Growth over 3 years; in Top Quartile
  • Other Expenses/Total Expenses is 22 %; Annual Growth is 46 %; Continuous Growth over 3 years; 5 Year CAGR is 22 %
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Shivalik Rasayan lifts Medicamen Biotech stake to 42.57% via warrant conversion
Read More
  • Past/current
Medicamen Biotech (NSE:MEDICAMEQ) Allots 5,00,000 Equity Shares on Conversion of Warrants
Read More
  • Past/current
Medicamen Biotech Lower Circuit Today: Price, Data and Peers
Read More
  • Past/current